Boceprevir Approval Means Better Hep C Treatment Finally Available

[Guest guest]

Boceprevir Approval Means Better Hep C Treatment Finally Available

As the first FDA approved Hepatitis C protease inhibitor, boceprevir (Victrelis) has cleared the final hurdle and can now improve the general public's odds for beating the Hepatitis C virus.

Boceprevir Wins FDA Approval to Treat Hepatitis C

By P. , Washington Correspondent, MedPage Today

Published: May 13, 2011

WASHINGTON -- The FDA has approved the investigational drug boceprevir (Victrelis), to be used in combination with peginterferon and ribavirin, to treat hepatitis C genotype 1.

Boceprevir, made by Merck, will be the first HCV protease inhibitor to reach market and is expected to be a major advance in treating the disease, which affects between three and four million people in U.S.

Continue reading this entire article:http://www.medpagetoday.com/InfectiousDisease/Hepatitis/26469

http://www.hepatitis-central.com/mt/archives/2011/05/boceprevir_appr.html